COX-2 inhibitors and other NSAIDs in bladder and prostate cancer.
Sabichi
Anita L
AL
Department of Clinical Cancer Prevention, University of Texas M.D. Anderson Cancer Center, Houston, Tex., USA. asabichi@mail.mdanderson.org
Lippman
Scott M
SM
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004041:Dietary Fats / Q000009:adverse effects; D006801:Humans; D007527:Isoenzymes / Q000032:analysis / Q000037:antagonists & inhibitors*; D008297:Male; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases / Q000032:analysis; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000453:epidemiology / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000201:enzymology / Q000453:epidemiology / Q000517:prevention & control*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D004041:Dietary Fats; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases